Genetic test approved for use on NHS could save thousands of women from chemotherapy every year
Treatment could benefit those with early-stage breast cancer facing the intensive treatment
Wednesday 25 September 2013
Thousands of women with breast cancer could be spared chemotherapy every year thanks to a test which has been approved for use on the NHS.
The genetic test could benefit those with early-stage breast cancer facing the intensive treatment, whose side effects include nausea, vomiting, insomnia, hair loss and fatigue.
Studies have suggested that half of women with the most common form of early breast cancer could be spared chemotherapy if they have the test.
The Oncotype DX test involves the examination of genes taken from a sample of a tumour removed during surgery.
It can help doctors decide whether chemotherapy would actually benefit patients and the risk of cancer returning.
Almost 50,000 people are diagnosed with breast cancer every year in the UK and most of these have early-stage disease.
Doctors will use the test in combination with other information, such as the size and grade of the tumour, to work out if chemotherapy could be beneficial.
Current evidence suggests some people are over or under-treated because of uncertainties about whether their cancer will actually spread.
The National Institute for Health and Clinical Excellence (Nice) has approved the Oncotype DX test for people with oestrogen receptor positive (ER+), lymph node negative (LN-) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer who are at intermediate risk of the cancer spreading.
Professor Carole Longson, Nice health technology evaluation centre director, said: "Breast cancer patients face significant emotional and psychological strain when considering chemotherapy.
"A test that can help to predict better the risk of the breast cancer spreading, and therefore the potential likely benefit of additional chemotherapy, represents a significant step forward for patients."
Some 15 studies on more than 6,000 patients worldwide have taken place using Oncotype DX, showing that around one third of treatment plans are changed as a result of the test.
A 2011 UK study on Oncotype DX found that 46% of patients with early stage disease could be spared unnecessary chemotherapy.
The research was carried out by Simon Holt, a breast surgeon at the Hywel Dda Local Health Board in Wales, on 142 NHS patients with oestrogen receptor positive breast cancer, the most common type.
Commenting on the Nice announcement, Kathi Apostolidis, vice president of the European Cancer Patient Coalition based in Brussels, said: "The decision of whether or not to undergo chemotherapy is an extremely important and difficult one for patients, not only due to the many side effects associated with treatment, but also due to the hardship for the patient and her family and the loss of income due to days off work.
"Allowing patients and their physicians to make more personalised treatment decisions can help improve outcomes for the rising number of early-stage breast cancer patients in Europe."
Diving in at the deep end is no excuse for shirking the style stakes
- 2 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
- 3 Why I'm on the brink of burning my Israeli passport
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Loom bands: Bids for dress made from colourful rubber reach almost £154,000 on eBay
Israel-Gaza crisis: Eight killed in Gaza Strip cafe while watching World Cup semi-final
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
There’s a nasty smell in the political air – and it’s coming from the Tories
£50000 - £70000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
competitive: Progressive Recruitment: My client, a FTSE 100 organisation are u...
£300 - £350 per day + competitive: Orgtel: My client, a leading bank, is curre...
£33000 per annum + pension, 25 days holiday: Ashdown Group: A highly successfu...